U.S. Markets open in 4 hrs 52 mins

Albany Molecular Research, Inc. (AMRI)

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Add to watchlist
21.75+0.04 (+0.18%)
At close: 4:00PM EDT
People also watch

Albany Molecular Research, Inc.

26 Corporate Circle
Albany, NY 12203
United States

Full Time Employees3,085

Key Executives

Dr. Thomas E. D’Ambra Ph.D.Co-Founder & ChairmanN/AN/A61
Mr. William S. MarthPres, CEO & Director702.49kN/A62
Ms. Felicia I. LadinSr. VP, CFO & Treasurer413.04kN/A45
Mr. George SvokosChief Operating Officer503.51kN/A59
Dr. Steven R. Hagen Ph.D.Sr. VP of Quality & Compliance388.61k32.85k56
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Albany Molecular Research, Inc., a contract research and manufacturing company, provides integrated drug discovery, development, and manufacturing services primarily in the United States, Europe, and Asia. The company’s Discovery and Development Services segment offers services from target identification tools to investigational new drug enabling activities, such as diverse chemistry library design and synthesis, high throughput and high content screening, medicinal chemistry, and biology, as well as pharmacology, including drug metabolism and pharmacokinetics. It also provides analytical chemistry and testing services for drug discovery, and pharmaceutical development and manufacturing; and chemical development technologies to promote the solutions for route development from late lead optimization to commercial manufacturing. Its Active Pharmaceutical Ingredients segment offers chemical synthesis and manufacturing services in accordance with current good manufacturing practice (cGMP) regulations. The company’s Drug Product segment provides integrated pharmaceutical drug development programs and services, including process research and development, pre-formulation and formulation development, and GLP bioanalytical and separation sciences; formulation development services for solid dosage, solution, suspension, topicals, and injectables; and cGMP contract manufacturing services in sterile syringe and vial filling using specialized technologies, including lyophilization. Its Fine Chemical segment provides lab to commercial scale synthesis of reagents, and various compounds to the pharmaceutical, agrochemical, detergent, and cosmetic industries. The company serves pharmaceutical and biotechnology companies; government research entities and non-profit organizations; and agriculture, fine chemicals, contract chemical manufacturing, medical devices, and flavoring and cosmetics businesses. The company was founded in 1991 and is headquartered in Albany, New York.

Corporate Governance

Albany Molecular Research, Inc.’s ISS Governance QualityScore as of August 1, 2017 is 7. The pillar scores are Audit: 5; Board: 6; Shareholder Rights: 8; Compensation: 6.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.